Hot Investor Mandate 3: China-based Fund Seeks Clinical-stage Molecular Diagnostics, Drugs and Devices

2 Feb

A private investment firm based in Beijing, China, is investing from its 300 million RMB (US$50 million) fund into early stage ventures in the life sciences and healthcare sector. Typical allocation size ranges from US$0.5-5 million. The firm can either lead or follow in a financing round. The firm is seeking opportunities from China and the US.

The firm works on a wide range of life science sectors including biopharmaceuticals, medical devices, diagnostics, life science R&D, and medical services. The firm is especially interested in clinical stage molecular diagnostic products, while it would also consider preclinical stage projects with a lesser interest. The firm is agnostic to disease indications.

The firm is looking for experienced management team with proven products. The firm can assist with registration and distribution in China by leveraging its network of pharma partners, CRO/CMO, academic centers, and distribution channels. The firm is interested in distribution rights in China and may request board representation on a case-by-case basis.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com

Leave a Reply

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out / Change )

Twitter picture

You are commenting using your Twitter account. Log Out / Change )

Facebook photo

You are commenting using your Facebook account. Log Out / Change )

Google+ photo

You are commenting using your Google+ account. Log Out / Change )

Connecting to %s

%d bloggers like this: